Trial Profile
MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Fluoxetine (Primary)
- Indications Cognition disorders; Depressive disorders
- Focus Adverse reactions
- Acronyms MAMBO
- 22 Feb 2021 Status changed from active, no longer recruiting to completed.
- 25 Dec 2020 Planned End Date changed from 31 Mar 2021 to 6 Jan 2021.
- 25 Dec 2020 Planned primary completion date changed from 1 Dec 2020 to 6 Jan 2021.